MGC Pharma’s pioneering cannabis-based treatment for refractory epilepsy now available to patients in the United Kingdom LONDON, May 31, 2023 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.